|
1.
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000.
|
|
2.
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011.
|
|
3.
|
Takahashi K and Yamanaka S: Induction of
pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell. 126:663–676. 2006.
|
|
4.
|
Takahashi K, Tanabe K, Ohnuki M, et al:
Induction of pluripotent stem cells from adult human fibroblasts by
defined factors. Cell. 131:861–872. 2007.
|
|
5.
|
Yamanaka S: Elite and stochastic models
for induced pluripotent stem cell generation. Nature. 460:49–52.
2009.
|
|
6.
|
Miyoshi N, Ishii H, Nagai K, et al:
Defined factors induce reprogramming of gastrointestinal cancer
cells. Proc Natl Acad Sci USA. 107:40–45. 2010.
|
|
7.
|
Nagai K-i, Ishii H, Miyoshi N, et al:
Long-term culture following ES-like gene-induced reprogramming
elicits an aggressive phenotype in mutated cholangiocellular
carcinoma cells. Biochem Biophysic Res Commun. 395:258–263.
2010.
|
|
8.
|
Zhao Y, Yin X, Qin H, et al: Two
supporting factors greatly improve the efficiency of human iPSC
generation. Cell Stem Cell. 3:475–479. 2008.
|
|
9.
|
Kawamura T, Suzuki J, Wang YV, et al:
Linking the p53 tumour suppressor pathway to somatic cell
reprogramming. Nature. 460:1140–1144. 2009.
|
|
10.
|
Hong H, Takahashi K, Ichisaka T, et al:
Suppression of induced pluripotent stem cell generation by the
p53-p21 pathway. Nature. 460:1132–1135. 2009.
|
|
11.
|
Moon JH, Ishii H, Dewi DL, et al:
Gain-of-function oncogenic mutations in TP53 enhance defined
factor-mediated cellular reprogramming. Nat Preced. 2011.
View Article : Google Scholar
|
|
12.
|
Yoshida Y, Takahashi K, Okita K, et al:
Hypoxia enhances the generation of induced pluripotent stem cells.
Cell Stem Cell. 5:237–241. 2009.
|
|
13.
|
Hoshino H, Nagano H, Haraguchi N, et al:
Hypoxia and TP53 deficiency for induced pluripotent stem cell-like
properties in gastrointestinal cancer. Int J Oncol. 40:1423–1430.
2012.
|
|
14.
|
Anokye-Danso F, Trivedi CM, Juhr D, et al:
Highly efficient miRNA-mediated reprogramming of mouse and human
somatic cells to pluripotency. Cell Stem Cell. 8:376–388. 2011.
|
|
15.
|
Miyoshi N, Ishii H, Nagano H, et al:
Reprogramming of mouse and human cells to pluripotency using mature
microRNAs. Cell Stem Cell. 8:633–638. 2011.
|
|
16.
|
Lin SL, Chang DC, Ying SY, et al: MicroRNA
miR-302 inhibits the tumorigenecity of human pluripotent stem cells
by coordinate suppression of the CDK2 and CDK4/6 cell cycle
pathways. Cancer Res. 70:9473–9482. 2010.
|
|
17.
|
Lin SL, Chang DC, Chang-Lin S, et al:
Mir-302 reprograms human skin cancer cells into a pluripotent
ES-cell-like state. RNA. 14:2115–2124. 2008.
|
|
18.
|
Fareh M, Turchi L, Virolle V, et al: The
miR 302-367 cluster drastically affects self-renewal and
infiltration properties of glioma-initiating cells through CXCR4
repression and consequent disruption of the SHH-GLI-NANOG network.
Cell Death Differ. 19:232–244. 2012.
|
|
19.
|
Dexter DL and Leith JT: Tumor
heterogeneity and drug resistance. J Clin Oncol. 4:244–257.
1986.
|
|
20.
|
Adams JM and Strasser A: Is tumor growth
sustained by rare cancer stem cells or dominant clones? Cancer Res.
68:4018–4021. 2008.
|
|
21.
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001.
|
|
22.
|
Bonnet D and Dick JE: Human acute leukemia
is organized as a hierarchy that originates from a primitive
hematopoietic cell. Nat Med. 3:730–737. 1997.
|
|
23.
|
Prince ME, Sivanandan R, Kaczorowski A, et
al: Identification of a subpopulation of cells with cancer stem
cell properties in head and neck squamous cell carcinoma. Proc Natl
Acad Sci USA. 104:973–978. 2007.
|
|
24.
|
Haraguchi N, Utsunomiya T, Inoue H, et al:
Characterization of a side population of cancer cells from human
gastrointestinal system. Stem Cells. 24:506–513. 2006.
|
|
25.
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human
colon-cancer-initiating cells. Nature. 445:111–115. 2007.
|
|
26.
|
O’Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immuno-deficient mice. Nature. 445:106–110. 2007.
|
|
27.
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
et al: Prospective identification of tumorigenic breast cancer
cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003.
|
|
28.
|
Piccirillo SG, Reynolds BA, Zanetti N, et
al: Bone morphogenetic proteins inhibit the tumorigenic potential
of human brain tumour-initiating cells. Nature. 444:761–765.
2006.
|
|
29.
|
Bao S, Wu Q, McLendon RE, et al: Glioma
stem cells promote radioresistance by preferential activation of
the DNA damage response. Nature. 444:756–760. 2006.
|
|
30.
|
Bixby S, Kruger GM, Mosher JT, et al:
Cell-intrinsic differences between stem cells from different
regions of the peripheral nervous system regulate the generation of
neural diversity. Neuron. 35:643–656. 2002.
|
|
31.
|
Sagar J, Chaib B, Sales K, et al: Role of
stem cells in cancer therapy and cancer stem cells: a review.
Cancer Cell Int. 7:92007.
|
|
32.
|
Zhong J and Dai LC: Targeting liposomal
nanomedicine to cancer therapy. Technol Cancer Res Treat. Mar
28–2012, (Epub ahead of print).
|
|
33.
|
Hurt EM, Chan K, Serrat MA, et al:
Identification of vitronectin as an extrinsic inducer of cancer
stem cell differentiation and tumor formation. Stem Cells.
28:390–398. 2010.
|
|
34.
|
Yu CH, Law JB, Suryana M, et al: Early
integrin binding to Arg-Gly-Asp peptide activates actin
polymerization and contractile movement that stimulates outward
translocation. Proc Natl Acad Sci USA. 108:20585–20590. 2011.
|
